Chemistry:4-AcO-MALT

From HandWiki

4-AcO-MALT, also known as 4-acetoxy-N-methyl-N-allyltryptamine, is a psychedelic drug of the tryptamine family.[1][2][3] It is the acetate ester of 4-HO-MALT.[1][2][3]

Use and effects

Interactions

Pharmacology

Pharmacodynamics

4-AcO-MALT is assumed to act as a prodrug of the serotonergic psychedelic 4-HO-MALT.[1] 4-HO-MALT is a serotonin receptor modulator, including acting as an agonist of the serotonin 5-HT2 receptors.[2] The receptor interactions of 4-AcO-MALT have also been studied.[2][3]

Chemistry

Analogues

Analogues of 4-AcO-MALT include methylallyltryptamine (MALT), 4-HO-MALT (maltocin), 5-MeO-MALT, 4-AcO-DMT (psilacetin), 4-AcO-MET (metacetin), 4-AcO-MPT, 4-AcO-MiPT (mipracetin), and 4-AcO-DALT, among others.

History

4-AcO-MALT was first described in the scientific literature by at least 2021.[1] It has been encountered as a novel designer drug.[4][5]

See also

References

  1. 1.0 1.1 1.2 1.3 "Psilacetin derivatives: fumarate salts of the methyl–ethyl, methyl–allyl and diallyl variants of the psilocin prodrug". Acta Crystallographica Section E 77 (Pt 2): 101–106. 1 February 2021. doi:10.1107/S2056989021000116. ISSN 2056-9890. PMID 33614134. Bibcode2021AcCrE..77..101P. 
  2. 2.0 2.1 2.2 2.3 "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacology & Translational Science 6 (4): 567–577. April 2023. doi:10.1021/acsptsci.2c00222. PMID 37082754. 
  3. 3.0 3.1 3.2 "The polypharmacology of psychedelics reveals multiple targets for potential therapeutics". Neuron. July 2025. doi:10.1016/j.neuron.2025.06.012. PMID 40683247. https://www.cell.com/cms/10.1016/j.neuron.2025.06.012/attachment/7d8365fe-51f3-4a28-bf40-9999bec837f6/mmc11.pdf. 
  4. "New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory". Clinical Biochemistry 133-134. 2024. doi:10.1016/j.clinbiochem.2024.110810. PMID 39181179. 
  5. "Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis". Basic & Clinical Pharmacology & Toxicology 131 (5): 420–434. 2022. doi:10.1111/bcpt.13786. ISSN 1742-7835. PMID 36028947.